Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2016

View Archived Issues

Trial supports the use of sodium channel blocker phenytoin in acute optic neuritis

Pivotal phase III clinical trial of intravenous meloxicam begins at Recro Pharma

FDA accepts BLA for bezlotoxumab

Supinoxin demonstrates preclinical efficacy to treat renal cancer

Replikins selects peptide Zika virus vaccine for preclinical efficacy studies

Sumitomo Dainippon Pharma updates progress of third quarter of fiscal 2015

Blend Therapeutics secures Series C financing and changes name

Urine-exosome signature validated in prostate cancer patients

Roche Diagnostics and Lilly to develop Alzheimer's diagnostic

Stemedica completes enrollment in phase I/IIa study in stroke

MSI Methylation Sciences reports results from phase II trial of MSI-195 in MDD

Alpharmagen discloses nicotinic acetylcholine alpha7 modulators

University of Texas System patents mitochondrial GLS inhibitors

Serendex starts phase II trial of inhaled molgramostim in ARDS

BIND Therapeutics gives update on BIND-014 trials

ImmunoCellular Therapeutics enters research agreement with the University of Maryland

Aprecia Pharmaceuticals obtains financing to advance 3D-printed drug pipeline

Clovis begins phase Ib/II study of atezolizumab and rociletinib

Cyramza approved in Europe for NSCLC and colorectal cancer

First patient dosed in Zimura phase II/III trial

Breakthrough therapy designation for venetoclax for AML

Incyte to stop substudy within ruxolitinib phase II colorectal cancer study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 7, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...